{"id":2674,"date":"2014-08-04T22:16:00","date_gmt":"2014-08-04T22:16:00","guid":{"rendered":"https:\/\/cdafound.org\/?p=2674"},"modified":"2020-11-25T22:28:26","modified_gmt":"2020-11-25T22:28:26","slug":"enhanced-antiviral-treatment-efficacy-and-uptake-in-preventing-the-rising-burden-of-hepatitis-c-related-liver-disease-and-costs-in-australia","status":"publish","type":"post","link":"https:\/\/dnc-test.myddns.me\/cda-foundation\/cdafound.org\/enhanced-antiviral-treatment-efficacy-and-uptake-in-preventing-the-rising-burden-of-hepatitis-c-related-liver-disease-and-costs-in-australia\/","title":{"rendered":"Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia"},"content":{"rendered":"\n
\"Journal<\/figure><\/div>\n\n\n\n

Sievert W, Razavi H, Estes C, Thompson AJ, Zekry A, Roberts SK, Dore GJ. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia. J Gastroenterol Hepatol. 2014 Aug;29 Suppl 1:1-9. doi: 10.1111\/jgh.12677. PMID: 25055928.<\/a><\/p>\n\n\n\n
\n\n\n\n

\n\n\n\n

Summary<\/h2>\n\n\n\n

Background and aim<\/h3>\n\n\n\n

Chronic hepatitis C virus (HCV) infection is an important cause of advanced liver disease and liver-related deaths in Australia. Our aim was to describe the burden of HCV infection and consider treatment strategies to reduce HCV-related morbidity and mortality.<\/p>\n\n\n\n

Methods<\/h3>\n\n\n\n

Baseline model parameters were based upon literature review and expert consensus with a focus on Australian data. Three treatment scenarios based on anticipated introduction of improved direct-acting antiviral regimens were considered to reduce HCV disease burden. Scenario 1 evaluated the impact of increased treatment efficacy alone (to 80-90% by 2016). Scenario 2 evaluated increased efficacy and increased treatment uptake (2550 to 13,500 by 2018) without treatment restriction, while Scenario 3 considered the same increases with treatment limited to \u2265 F3 during 2015-2017.<\/p>\n\n\n\n

Results<\/h3>\n\n\n\n

In 2013, there were an estimated 233,490 people with chronic HCV infection: 13,850 with cirrhosis, 590 with hepatocellular carcinoma (HCC) and 530 liver-related deaths. If the current HCV treatment setting is unchanged, threefold increases in the number of people with cirrhosis, HCC, and liver disease deaths will be seen by 2030. Scenario 1 resulted in modest impacts on disease burden (4% decrease in HCC, decompensated cirrhosis, and liver deaths) and costs. Scenario 3 had the greatest impact on disease burden (approximately 50% decrease in HCC, decompensated cirrhosis, and liver deaths) and costs, while Scenario 2 had slightly lesser impact.<\/p>\n\n\n\n

Conclusions<\/h3>\n\n\n\n

Considerable increases in the burden of HCV-related advanced liver disease and its complications will be seen in Australia under current treatment levels and outcomes. Introduction of improved direct-acting antiviral regimens with enhanced efficacy at current treatment levels will lead to limited impacts on this disease burden. A combination of increased treatment efficacy and greater uptake is required to achieve major reductions in advanced liver disease and related costs.<\/p>\n\n\n\n

Countries:<\/strong> Australia<\/p>\n","protected":false},"excerpt":{"rendered":"

Sievert W, Razavi H, Estes C, Thompson AJ, Zekry A, Roberts SK, Dore GJ. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia. J Gastroenterol Hepatol. 2014 Aug;29 Suppl 1:1-9. doi: 10.1111\/jgh.12677. PMID: 25055928. Summary Background and aim Chronic hepatitis C virus (HCV) infection […]<\/p>\n","protected":false},"author":24,"featured_media":3322,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[9],"tags":[32,10],"publication-author":[],"class_list":["post-2674","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-publication","tag-economic-impact","tag-hcv"],"acf":[],"_links":{"self":[{"href":"https:\/\/dnc-test.myddns.me\/cda-foundation\/cdafound.org\/wp-json\/wp\/v2\/posts\/2674","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dnc-test.myddns.me\/cda-foundation\/cdafound.org\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dnc-test.myddns.me\/cda-foundation\/cdafound.org\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dnc-test.myddns.me\/cda-foundation\/cdafound.org\/wp-json\/wp\/v2\/users\/24"}],"replies":[{"embeddable":true,"href":"https:\/\/dnc-test.myddns.me\/cda-foundation\/cdafound.org\/wp-json\/wp\/v2\/comments?post=2674"}],"version-history":[{"count":5,"href":"https:\/\/dnc-test.myddns.me\/cda-foundation\/cdafound.org\/wp-json\/wp\/v2\/posts\/2674\/revisions"}],"predecessor-version":[{"id":3398,"href":"https:\/\/dnc-test.myddns.me\/cda-foundation\/cdafound.org\/wp-json\/wp\/v2\/posts\/2674\/revisions\/3398"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dnc-test.myddns.me\/cda-foundation\/cdafound.org\/wp-json\/wp\/v2\/media\/3322"}],"wp:attachment":[{"href":"https:\/\/dnc-test.myddns.me\/cda-foundation\/cdafound.org\/wp-json\/wp\/v2\/media?parent=2674"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dnc-test.myddns.me\/cda-foundation\/cdafound.org\/wp-json\/wp\/v2\/categories?post=2674"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dnc-test.myddns.me\/cda-foundation\/cdafound.org\/wp-json\/wp\/v2\/tags?post=2674"},{"taxonomy":"publication-author","embeddable":true,"href":"https:\/\/dnc-test.myddns.me\/cda-foundation\/cdafound.org\/wp-json\/wp\/v2\/publication-author?post=2674"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}